Second malignancies after multiple myeloma: From 1960s to 2010s

Blood

Volumn 119, Issue 12, 2012, Pages 2731-2737

  Thomas, Anish ^a   Mailankody, Sham ^a   Korde, Neha ^a   Kristinsson, Sigurdur Y ^b   Turesson, Ingemar ^c   Landgren, Ola ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; LENALIDOMIDE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALCOHOL CONSUMPTION; BREAST CANCER; CANCER RADIOTHERAPY; CHROMOSOME ABERRATION; COLON CANCER; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; ESOPHAGUS CANCER; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECOND CANCER; SMOKING;

EID: 84858824788     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-381426     Document Type: Review

References (71)

1. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population- based study. J Clin Oncol. 2010;28(5):830- 834.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
3. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993-1999. (Pubitemid 46972782)
4. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354-1365. (Pubitemid 41487803)
5. Mauch PM, Kalish LA, Marcus KC, et al. Longterm survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J. 1995;1(1):33-42.
6. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498-509. (Pubitemid 30078531)
7. Curtis RE, Ron E, Ries LAG, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Institutes of Health; 2006.
8. Nordenson NG. Myelomatosis: a clinical review of 310 cases. Acta Med Scand Suppl. 1996;445: 178-86.
9. Osserman EF. In: Killander J, ed. Gamma Globulins: Structure and Control of Biosynthesis. Stockholm, Sweden: Almqvist and Wiksell; 1967:573.
10. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121-1125.
11. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979; 301(14):743-748. (Pubitemid 10250478)
12. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010; 85(3):225-230.
13. Finnish Leukaemia Group. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma. Eur J Haematol. 2000;65(2):123-127.
14. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer. 2001;85(7):997-1005. (Pubitemid 33016003)
15. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS). Blood. 2011; 118(15):4086-4092.
16. Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, second edition to International Classification of Diseases for Oncology, 3rd ed. Cancer Statistics Branch, DCCPS, SEER Program, National Cancer Institute. 2001 [cited 2011 July 22]. Available at http://seer.cancer.gov/ tools/conversion/ICDO2-3manual.pdf.
17. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98(1):15- 25.
18. Hasskarl J, Ihorst G, De Pasquale D, et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma. 2011; 52(2):247-259.
19. Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalanbased autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008;111(1): 94-100.
20. Przepiorka D, Buadi F, McClune B, Franz G, Walsh W, White F. Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant. 2007;40(8):759-764. (Pubitemid 47521535)
21. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95(2):349-353. (Pubitemid 26360224)
22. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis: a report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer. 1987;55(5):523-529. (Pubitemid 17098861)
23. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985;103(2): 195-200. (Pubitemid 15000568)
24. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986; 105(3):360-367.
25. Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: II. Leukemia and myeloma. Cancer. 2005;103(2):393-401. (Pubitemid 40129300)
26. Sigurdson AJ, Jones IM. Second cancers after radiotherapy: any evidence for radiation-induced genomic instability? Oncogene. 2003;22(45): 7018-7027. (Pubitemid 37386670)
27. de Gonzalez AB, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011; 12(4):353-360.
28. Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch populationbased study. J Clin Oncol. 2008;26(8):1239-1246.
29. Berrington de Gonzalez A, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102(1):220-226.
30. Attal M, Cances Lauwers V, eds. Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial. Paris, France: 13th International Myeloma Workshop; 2011.
31. McCarthy P, Anderson K. Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma CALGB ECOG BMT-CTN 100104. Paris, France: 13th International Myeloma Workshop; 2011.
32. PalumboAP, Catalano J, eds. Incidence of second primary malignancy in melphalan-prednisonelenalidomide combination followed by lenalidomide maintenance in newly diagnosed multiple myeloma patients age 65 or older [abstract]. J Clin Oncol. 2011;(suppl):29.
33. Reece DE, Goswami RS, eds. Incidence and characteristics of secondary myelodysplastic syndrome developing during lenalidomide-based regimens in relapsed and/or refractory multiple myeloma patients. Orlando, FL: 53rd American Society of Hematology Annual Meeting; December 4, 2010.
34. Dimopoulos MA, Niesvizky R. Lenalidomide and dexamethasone treatment in relapsed/refractory multiple myeloma patients and risk of second primary malignancies: analysis of MM-009/010 [abstract]. J Clin Oncol. 2011;(suppl):29.
35. Kuendgen A, Lauseker M, List AF, et al. Lenalidomide treatment is not eelated to AML progression risk but is associated with a survival benefit in RBC transfusion-dependent patients with IPSS low- or Int-1-risk MDS with del5q: results from a comparative study. Blood (ASH Annual Meeting Abstracts). 2011;118:119.
36. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585- 598.
37. Zhan F, Sawyer J, Tricot G. The role of cytogenetics in myeloma. Leukemia. 2006;20(9):1484- 1486.
38. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283-289. (Pubitemid 28372321)
39. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-549. (Pubitemid 36159890)
40. Dahabreh IJ, Giannouli S, Gota V, Voulgarelis M. GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis. Int J Cancer. 2010;126(7): 1716-1723.
41. Allan JM, Travis LB. Mechanisms of therapyrelated carcinogenesis. Nat Rev Cancer. 2005; 5(12):943-955.
42. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999; 94(5):1814-1819. (Pubitemid 29411333)
43. Amigo ML, del Canizo MC, Hernandez JM, et al. Clonal myelodysplastic cells present in apheresis product before transplantation. Leukemia. 1998; 12(9):1497-1499. (Pubitemid 28442402)
44. Goswami RS, Masih-Khan E, eds. Characteristics of patients presenting with secondary myelodysplastic syndrome during treatment with lenalidomide for relapsed/refractory multiple myeloma: 5q deletions can be observed. Orlando, FL: 53rd American Society of Hematology Annual Meeting; December 4, 2010.
45. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363(11): 1025-1037.
46. Jadersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica. 2009;94(12):1762-1766.
47. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood. 1994;84(10):3253-3260.
48. Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS. Advances in the 5q-syndrome. Blood. 2010;116(26):5803-5811.
49. Landgren O. Multiple myeloma precursor disease: current clinical dilemma and future opportunities. Semin Hematol. 2011;48(1):1-3.
50. Knight JA, Skol AD, Shinde A, et al. Genomewide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 2009;113(22):5575-5582.
51. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapyrelated acute myeloid leukemia susceptibility. Blood. 2008;112(3):741-749.
52. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1(2):133-143. (Pubitemid 41039160)
53. Shimizu Y, Schull WJ, Kato H. Cancer risk among atomic bomb survivors: the RERF Life Span Study. Radiation Effects Research Foundation. JAMA. 1990;264(5):601-604. (Pubitemid 20241442)
54. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994;137(2 suppl):S68-S97. (Pubitemid 24060247)
55. Iwanaga M, Hsu WL, Soda M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29(4):428-434.
56. Iwanaga M, Tagawa M, Tsukasaki K, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood. 2009;113(8):1639-1650.
57. Landgren O. A role for ionizing radiation in myelomagenesis? Blood. 2009;113(8):1616-1617.
58. Gold LS, Stewart PA, Milliken K, et al. The relationship between multiple myeloma and occupational exposure to six chlorinated solvents. Occup Environ Med. 2011;68(6):391-399.
59. Sonoda T, Ishida T, Mori M, Sakai H, Noguchi M, Imai K. A case-control study of multiple myeloma in Japan: association with occupational factors. Asian Pac J Cancer Prev. 2005;6(1):33-36.
60. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111(7):3388-3394.
61. Kristinsson SY, Goldin LR, Bjorkholm M, Koshiol J, Turesson I, Landgren O. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica. 2009;94(11):1581-1589.
62. Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21): 2897-2903.
63. Gale RP, Opelz G. Commentary: does immune suppression increase risk of developing acute myeloid leukemia? [published online ahead of print August 26, 2011] Leukemia. doi:10.1038/leu.2011.224.
64. Kristinsson SY, Derolf AR, Edgren G, Dickman PW, Bjorkholm M. Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden. J Clin Oncol. 2009;27(12):2073-2080.
65. Brown LM, Gibson R, Burmeister LF, Schuman LM, Everett GD, Blair A. Alcohol consumption and risk of leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Leuk Res. 1992;16(10):979-984.
66. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20(4):637-664. (Pubitemid 350215374)
67. Friedman GD, Herrinton LJ. Obesity and multiple myeloma. Cancer Causes Control. 1994;5(5): 479-483. (Pubitemid 24302712)
68. Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116(7):1056-1059.
69. Brown LM, Gridley G, Pottern LM, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control. 2001;12(2):117-125. (Pubitemid 32165269)
70. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011;365(23):2241-2242.
71. Edwards GA, Zawadzki ZA. Extraosseous lesion in plasma cell myeloma. A report of six cases. Am J Med. 1967;43(2):194-205.